Earnings Novo Nordisk’s US Offensive and Buyback Battle a Steidous Share Price Slide
The Danish pharmaceutical giant Novo Nordisk is executing a multi-pronged strategy to regain ground in the crucial US weight-loss drug market, even as its share price languishes near multi-year lows....